Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4CNS 4Breast 4Other solid neoplasm 2Gynecologic 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Paclitaxel 108Carboplatin 97pembrolizumab 64Cisplatin 63Cyclophosphamide 45Bevacizumab 35Taxes 31Gemcitabine 28liposomal doxorubicin 27Topotecan 26fludarabine 25olaparib 22Nivolumab 20Docetaxel 20Radiotherapy 18Brachytherapy 17veliparib 16Magnetic Resonance Spectroscopy 16Doxorubicin 16Biopsy 15Radiation 14niraparib 13aldesleukin 13Specimen Handling 13Platinum 13Oxaliplatin 13Filgrastim 13Albumin-Bound Paclitaxel 12atezolizumab 11Interleukin-2 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Colony-Stimulating Factors × Gynecologic × Clear all
NCT00436254 2025-04-06

Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

University of Washington

Phase 1 Completed
66 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

NCT02470559 2016-02-17

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent

Barbara Ann Karmanos Cancer Institute

Phase 1 Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡